Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients

被引:21
|
作者
Toth, Kinga [1 ]
Patai, Arpad V. [1 ]
Kalmar, Alexandra [1 ,2 ]
Bartak, Barbara Kinga [1 ]
Nagy, Zsofia Brigitta [1 ]
Galamb, Orsolya [2 ]
Wichmann, Barnabas [2 ]
Tulassay, Zsolt [1 ,2 ]
Molnar, Bela [1 ,2 ]
机构
[1] Semmelweis Univ, Dept Internal Med 2, Szentkiralyi Utca 46, H-1088 Budapest, Hungary
[2] Hungarian Acad Sci, Mol Med Res Unit, Budapest, Hungary
关键词
SEPT9; Colorectal cancer; Tumormarkers; Circadian rhythm; Cell-free DNA; BREAST-CANCER; CLOCK; PLASMA; BLOOD; PROGRESSION; EXERCISE; INFLAMMATION; CORTISOL; BEHAVIOR; SLEEP;
D O I
10.1007/s12253-016-0174-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine the level of cell-free DNA (cfDNA), Septin 9 (SEPT9) and tumor markers (CEA, AFP, CA19-9, TPA, CA72-4). Plasma samples were collected four times a day (06:00, 12:00, 18:00, 24:00) from 9 patients with CRC (5 stage I-II, 4 stage III-IV), from one with colorectal adenoma and from one healthy control. CfDNA was isolated, quantified and bisulfite-converted. CfDNA and methylated SEPT9 were determined by RT-PCR. Plasma levels of conventional tumor markers were also measured. The lowest cfDNA concentrations were observed at 24:00 and 18:00 in stage I-III patients. In stage IV samples low cfDNA level (mean 48.2 ng/ml) were observed at several time points (6:00, 12:00, 18:00). The highest cfDNA levels were measured at 6:00 and 12:00 in CRC I-III stages and at 24:00 in stage IV samples (78.65 ng/ml). Higher in-day differences were found in stage II (43-48%) than in stage I samples (22%). Interestingly, the highest SEPT9 methylation level was found at 24:00 in most CRC cases, in contrast to the cfDNA levels. At 24:00, all cancer and adenoma cases were positive for SEPT9 methylation. At other time points (6:00, 12:00, 18:00) only 77.7% of CRC samples showed SEPT9 positivity. Stage I samples were SEPT9 positive only at 24:00. CEA and CA19-9 levels displayed correlation with the amount of cfDNA in case of late stage cases. Daytime activity can influence SEPT9 positivity in cases with low concentration of cfDNA. Thus, it may improve screening sensitivity by collecting samples earlier in the morning.
引用
收藏
页码:699 / 706
页数:8
相关论文
共 50 条
  • [41] Cell-free circulating tumor DNA monitoring in pancreatic cancer patients
    Balendran-Braun, S.
    Kieler, M.
    Liebmann-Reindl, S.
    Prager, G. W.
    Streubel, B.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 455 - 455
  • [42] Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients
    Bach, Sander
    Wever, Birgit M. M.
    van de Wiel, Mark A.
    Veltman, Joris D.
    Hashemi, Sayed M. S.
    Kazemier, Geert
    Bahce, Idris
    Steenbergen, Renske D. M.
    EPIGENETICS, 2022, 17 (10) : 1057 - 1069
  • [43] Cell-free circulating tumor DNA in colorectal cancer: a proof of concept with simplified methodology
    Bosque, Javier
    Guirao, Carlos
    Ferrandez, Asia
    Suarez, Noelia
    Isabel Castillejo, Maria
    Anguita, Diana
    Pamies, Maria
    Moya, Alejandro
    Luis Soto, Jose
    Gallego Plazas, Javier
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (10): : 1924 - 1931
  • [44] Cell-free circulating tumor DNA in colorectal cancer: a proof of concept with simplified methodology
    Javier Bosque
    Carlos Guirao
    Asia Ferrández
    Noelia Suarez
    Maria Isabel Castillejo
    Diana Anguita
    María Pamies
    Alejandro Moya
    José Luis Soto
    Javier Gallego Plazas
    Clinical and Translational Oncology, 2022, 24 : 1924 - 1931
  • [45] Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer
    Stasik, Sebastian
    Mende, Marika
    Schuster, Caroline
    Mahler, Sandra
    Aust, Daniela
    Tannapfel, Andrea
    Reinacher-Schick, Anke
    Baretton, Gustavo
    Krippendorf, Claudia
    Bornhaeuser, Martin
    Ehninger, Gerhard
    Folprecht, Gunnar
    Thiede, Christian
    FRONTIERS IN GENETICS, 2022, 12
  • [46] Detection of MSI in circulating cell-free DNA from colorectal cancer patients
    Bozdogan, S. Tug
    Rencuzogullari, C.
    Rencuzogullari, A.
    Bisgin, A.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1649 - 1649
  • [47] Cell-free DNA and exoDNA analysis in metastatic colorectal cancer patients (mCRC).
    Galvano, Antonio
    Castiglia, Marta
    Guarini, Aurelia
    Gristina, Valerio
    Cutaia, Sofia
    Bazan, Viviana
    Russo, Antonio
    Carreca, Ignazio Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients
    Bedin, Chiara
    Enzo, Maria Vittoria
    Del Bianco, Paola
    Pucciarelli, Salvatore
    Nitti, Donato
    Agostini, Marco
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (08) : 1888 - 1898
  • [49] Cell-free DNA and chemoembolization in patients with liver metastases from colorectal cancer
    Boysen, Anders Kindberg
    Jensen, Martin
    Nielsen, Dennis Tonner
    Mortensen, Frank Viborg
    Sorensen, Brita Singers
    Jensen, Anni Ravnsbaek
    Spindler, Karen-Lise
    ONCOLOGY LETTERS, 2018, 16 (02) : 2654 - 2660
  • [50] Methylated Septin 9 and Carcinoembryonic Antigen for Serological Diagnosis and Monitoring of Patients with Colorectal Cancer After Surgery
    Zhi Yao Ma
    Wai Lun Law
    Enders Kai On Ng
    Cherry Sze Yan Chan
    Kam Shing Lau
    Yuen Yee Cheng
    Vivian Yvonne Shin
    Ava Kwong
    Wai K. Leung
    Scientific Reports, 9